HCM Hutchison China Meditech Ltd Sponsored ADR

HUTCHMED to Announce 2023 Final Results

HUTCHMED to Announce 2023 Final Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

The English conference call and audio webcast will take place at 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on Wednesday, February 28, 2024. In addition to the usual English webcast, there will also be a Chinese (Putonghua) webcast at 7:30 pm EST / 12:30 am GMT / 8:30 am HKT on Thursday, February 29, 2024. Both webcasts will be available live via the company website at . The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: or follow us on .

CONTACTS

Investor Enquiries+852 2121 8200 /
  
Media Enquiries 
Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) /

Zhou Yi, Brunswick+852 9783 6894 (Mobile) /
  
Nominated Advisor 
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon+44 20 7886 2500



EN
01/02/2024

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

 PRESS RELEASE

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC Int...

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics — First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload — — Preclinical data shows robust antitumor activity with synergistic and bystander killing effects — HONG KONG and SHANGHAI ...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

China Healthcare Bi-Weekly: Seeing A Temporary Setback But Fundamental...

Investors took profits on the sector amid concerns over possibly worsening US-China geopolitical tensions. Following the largest share price gain in previous months, biotech and CRDMOs saw significant setbacks in the first two weeks of October. We believe the pullback is temporary as the trend of innovation and globalisation among Chinese biopharmas remains strong, driven by robust pipelines, growing product launches and earnings expansion. CRDMOs and internet healthcare companies also expect to...

Benjaphol Suthwanish ... (+11)
  • Benjaphol Suthwanish
  • Benyamin Mikael
  • Carol Dou Xiao Qin
  • Chong Lee Len
  • Claire Wang Kelai
  • Heidi Mo Jinghui
  • John Cheong Ming Chern
  • Sunny Chen
  • Suryaputra Wijaksana
  • Tanapon Cholkadidamrongkul
  • Tham Mun Hon

Regional Morning Meeting Notes: Thursday, October 16, 2025

Greater China Economics | Inflation September’s CPI inflation improved slightly to -0.3% yoy (+0.1ppt), with core CPI reaching a ytd high of 1.0% yoy. However, food prices remained weak (-4.4% yoy), led by a 17% yoy fall in pork prices. PPI deflation eased to -2.3% yoy (+0.6ppt), with broad recovery in mining and quarrying and raw metal materials. Looking ahead, look out for improvement in consumer goods PPI inflation, which should be indicative of a sustainable improvement in pricing power....

 PRESS RELEASE

HUTCHMED Announces Appointment of Independent Non-executive Director a...

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, hea...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: Elunate in China is already approved in colorectal and endometrial cancers; kidney cancer, the third indication, is currently under regulatory review. Successfully launching new indications for Elunate and the rest of the marketed portfolio will be key revenue growth drivers in China, with the most notable perhaps the recent Orpathys/Tagrisso approval based on SACHI data (representing a much larger lung cancer indication than the initial approved monotherapy indication). Outs...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch